Alaunos Therapeutics
TCRT
26 hedge funds and large institutions have $158K invested in Alaunos Therapeutics in 2025 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 6 closing their positions.
1.37% less ownership
Funds ownership: 4.33% → 2.97% (-1.4%)
7% less funds holding
Funds holding: 28 → 26 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
54% less capital invested
Capital invested by funds: $345K → $158K (-$186K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.88K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$1.34K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$564 |
| 4 |
BTI
Blue Trust Inc
Alpharetta,
Georgia
|
+$385 |
| 5 |
NS
NBC Securities
Birmingham,
Alabama
|
+$57 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$15.1K |
| 2 |
SPIA
Steward Partners Investment Advisory
New York
|
-$2.87K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$1.46K |
| 4 |
Raymond James Financial
St Petersburg,
Florida
|
-$480 |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$442 |
TCRT Hedge Fund Activity: Q3 2025 in Review
26 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q3 2025, worth a combined $158K — down 54% from $345K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of TCRT and 4 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 3 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $1.88K. The largest seller was UBS Group, cutting an estimated $15.1K.
- 26 institutional investors held Alaunos Therapeutics (TCRT) as of Q3 2025, down from 28 in Q2 2025.
- Funds reported $158K of Alaunos Therapeutics stock for Q3 2025, down 54% quarter-over-quarter.
- 4 funds opened new Alaunos Therapeutics positions in Q3 2025 and 6 closed out, a net change of -2 holders.
- The largest Alaunos Therapeutics buyer in Q3 2025 was Tower Research Capital (TRC), an estimated $1.88K added.
- The largest Alaunos Therapeutics seller in Q3 2025 was UBS Group, an estimated $15.1K sold.
Based on aggregated 13F filings for Q3 2025.